PMID- 32002591 OWN - NLM STAT- MEDLINE DCOM- 20210514 LR - 20210514 IS - 1619-7089 (Electronic) IS - 1619-7070 (Linking) VI - 47 IP - 8 DP - 2020 Jul TI - Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study. PG - 1852-1863 LID - 10.1007/s00259-020-04708-y [doi] AB - PURPOSE: Approximately 40-70% of biochemically persistent or recurrent prostate cancer (PCa) patients after radical prostatectomy (RPE) are oligo-metastatic in (68)gallium-prostate-specific membrane antigen positron emission tomography ((68)Ga-PSMA PET). Those lesions are frequently located outside the prostate bed, and therefore not cured by the current standards of care like external-beam radiotherapy (EBRT) of the prostatic fossa. This retrospective study analyzes the influence of oligo-metastases' site on outcome after metastasis-directed radiotherapy (MDR). METHODS: Retrospectively, 359 patients with PET-positive PCa recurrences after RPE were analyzed. Biochemical recurrence-free survival (BRFS) (prostate-specific antigen (PSA) < post-radiotherapy nadir + 0.2 ng/mL) was assessed using Kaplan-Meier survival and Cox regression analysis. RESULTS: All patients were initially clinically without distant metastases (cM0). Seventy-five patients had local recurrence within the prostatic fossa, 32 patients had pelvic nodal plus local recurrence, 117 patients had pelvic nodal recurrence, 51 patients had paraaortic lymph node metastases with/without locoregional recurrence, and 84 patients had bone or visceral metastases with/without locoregional recurrence. Median PSA before MDR was 1.2 ng/mL (range, 0.04-47.5). Additive androgen deprivation therapy (ADT) was given in 35% (125/359) of patients. Median PSA nadir after MDR was 0.23 ng/mL (range, < 0.03-18.30). After a median follow-up of 16 months (1-57), 239/351 (68%) patients had no biochemical recurrence. Patients with distant lymph node and/or distant metastases, the so-called oligo-body cohort, had an overall in-field control of 90/98 (91%) but at the same time, an ex-field progress of 44/96 (46%). In comparison, an ex-field progress was detected in 28/154 (18%) patients with local and/or pelvic nodal recurrence (oligo-pelvis group). Compared with the oligo-pelvis group, there was a significantly lower BRFS in oligo-body patients at the last follow-up. CONCLUSION: Overall, BRFS was dependent on patterns of metastatic disease. Thus, MDR of PSMA PET-positive oligo-metastases can be offered considering that about one-third of the patients progressed within a median follow-up of 16 months. FAU - Schmidt-Hegemann, N-S AU - Schmidt-Hegemann NS AUID- ORCID: 0000-0002-2091-3603 AD - Department of Radiation Oncology, University Hospital LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. Nina-Sophie.Hegemann@med.uni-muenchen.de. FAU - Kroeze, S G C AU - Kroeze SGC AD - Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland. FAU - Henkenberens, C AU - Henkenberens C AD - Department of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany. FAU - Vogel, M M E AU - Vogel MME AD - Department of Radiation Oncology, Technical University of Munich, Munich, Germany. AD - Institute of Radiation Medicine (IRM), Department of Radiation Sciences, Helmholtz Zentrum Munchen, Unterschleissheim, Munich, Germany. FAU - Kirste, S AU - Kirste S AD - Department of Radiation Oncology, University of Freiburg, Freiburg im Breisgau, Germany. FAU - Becker, J AU - Becker J AD - Department of Radiation Oncology, University Hospital Tubingen, Tubingen, Germany. FAU - Burger, I A AU - Burger IA AD - Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland. FAU - Derlin, T AU - Derlin T AD - Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany. FAU - Bartenstein, P AU - Bartenstein P AD - Department of Nuclear Medicine, University Hospital LMU Munich, Munich, Germany. FAU - Eiber, M AU - Eiber M AD - Department of Nuclear Medicine, Technical University Munich, Munich, Germany. FAU - Mix, M AU - Mix M AD - Department of Nuclear Medicine, University of Freiburg, Freiburg im Breisgau, Germany. FAU - la Fougere, Ch AU - la Fougere C AD - Department of Nuclear Medicine, University Hospital Tubingen, Tubingen, Germany. AD - German Cancer Consortium (DKTK), Partner Site Tubingen, Tubingen, Germany. AD - Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tubingen, Tubingen, Germany. FAU - Muller, A C AU - Muller AC AD - Department of Radiation Oncology, University Hospital Tubingen, Tubingen, Germany. FAU - Grosu, A L AU - Grosu AL AD - Department of Radiation Oncology, University of Freiburg, Freiburg im Breisgau, Germany. AD - German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany. FAU - Combs, S E AU - Combs SE AD - Department of Radiation Oncology, Technical University of Munich, Munich, Germany. AD - Institute of Radiation Medicine (IRM), Department of Radiation Sciences, Helmholtz Zentrum Munchen, Unterschleissheim, Munich, Germany. AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. FAU - Christiansen, H AU - Christiansen H AD - Department of Radiotherapy and Special Oncology, Medical School Hannover, Hannover, Germany. FAU - Guckenberger, M AU - Guckenberger M AD - Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland. FAU - Belka, C AU - Belka C AD - Department of Radiation Oncology, University Hospital LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. AD - German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20200130 PL - Germany TA - Eur J Nucl Med Mol Imaging JT - European journal of nuclear medicine and molecular imaging JID - 101140988 RN - 0 (Androgen Antagonists) RN - EC 3.4.21.77 (Prostate-Specific Antigen) SB - IM MH - *Androgen Antagonists MH - Humans MH - Male MH - Neoplasm Recurrence, Local/diagnostic imaging/radiotherapy MH - Positron Emission Tomography Computed Tomography MH - Prostate-Specific Antigen MH - Prostatectomy MH - *Prostatic Neoplasms/diagnostic imaging/radiotherapy/surgery MH - Retrospective Studies MH - Tomography, X-Ray Computed OTO - NOTNLM OT - Distribution OT - External-beam radiotherapy OT - PSMA OT - Prostate cancer OT - Recurrence EDAT- 2020/02/01 06:00 MHDA- 2021/05/15 06:00 CRDT- 2020/02/01 06:00 PHST- 2019/11/20 00:00 [received] PHST- 2020/01/22 00:00 [accepted] PHST- 2020/02/01 06:00 [pubmed] PHST- 2021/05/15 06:00 [medline] PHST- 2020/02/01 06:00 [entrez] AID - 10.1007/s00259-020-04708-y [pii] AID - 10.1007/s00259-020-04708-y [doi] PST - ppublish SO - Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1852-1863. doi: 10.1007/s00259-020-04708-y. Epub 2020 Jan 30.